BTIG analysts raised the price target for Liquidia Corporation (NASDAQ:LQDA) from $37 to $45 and kept a “Buy” rating. This ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation’s LQDA Yutrepia (treprostinil) ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025 ...

YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a ...

This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension ...

Investing.com -- Shares of Liquidia Technologies Inc (NASDAQ:LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA ...

YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics' request for preliminary injunction and a temporary ...

Shares of Liquidia Technologies Inc (NASDAQ: LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation ...